Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. “Due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback